50677-24-2

Basic information

• Product Name: N'-(2-CHLOROACETYL)BENZOHYDRAZIDE
• Synonyms: AKOS 92183;AKOS BBS-00006627;N'-(2-CHLOROACETYL)BENZOHYDRAZIDE
• CAS NO: 50677-24-2
• Molecular Formula: C₉H₉ClN₂O₂
• Molecular Weight: 212.63
• Mol File: 50677-24-2.mol
• Article Data: 24

Chemical Properties

• Melting Point: 163 °C
• Appearance: /
• CAS DataBase Reference: N'-(2-CHLOROACETYL)BENZOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N'-(2-CHLOROACETYL)BENZOHYDRAZIDE(50677-24-2)
• EPA Substance Registry System: N'-(2-CHLOROACETYL)BENZOHYDRAZIDE(50677-24-2)

Safety Data

• Hazardous Substances Data: 50677-24-2(Hazardous Substances Data)

Upstream product

• 613-94-5 benzoic acid hydrazide 
• 79-04-9 chloroacetyl chloride 
• 93-89-0 benzoic acid ethyl ester 
• 65-85-0 benzoic acid 
• 902779-63-9 (E)-N'-((4-oxo-4H-chromen-3-yl)methylene)benzohydrazide 

Downstream Products

• 1320161-98-5 2-phenyl-5-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-1,3,4-oxadiazole 
• 121564-79-2 2-Azidomethyl-5-phenyl-[1,3,4]thiadiazole 
• 1342816-82-3 2-cyanoethyl [(5-phenyl-1 ,3,4-thiadiazol-2-yl)methyl]dithiocarbamate 
• 85730-57-0 C-(5-Phenyl-[1,3,4]thiadiazol-2-yl)-methylamine 
• 1242457-01-7 tert-butyl trans-1-[4-{[2-cyclopentyl-2-{4-[(5-oxo-2-phenyl-5,6-dihydro-4H-1,3,4-oxadiazin-4-yl)methyl]phenyl}acetyl]amino}but-2-en-1-yl]cyclopropanecarboxylate 

Relevant articles and documents

Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction

Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction by small-molecule inhibitors is emerging cancer immunotherapy. A series of novel 1,3,4-oxadiazole derivatives were designed, synthesized, and evaluated for

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators

Based on the approach of merged pharmacophores of GPR119 agonists and DPP-4 inhibitors, a series of tetrahydropyridopyrimidine compounds were designed as dual GPR119 and DPP-4 modulators with hypoglycemic activity. Seven fragments extracted from DPP-4 inhibitors were hybridized with the scaffold of tetrahydropyridopyrimidine. Among them, compound 51 displayed most potent GPR119 agonistic activity (EC50 = 8.7 nM) and good inhibition rate of 74.5% against DPP-4 at 10 μM. Furthermore, the blood glucose AUC0-2h of 51 was reduced to 19.5% in the oral glucose tolerance test (oGTT) at the dose of 30 mg/kg in C57BL/6N mice, which was more potent than that of vildagliptin (16.4%) at the same dose. The docking study of compound 51 with DPP-4 indicated GPR119 agonists could inhibit DPP-4 to serve as dual GPR119 and DPP-4 modulators.